Teva Pharmaceutical Industries Ltd (TEVA): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Teva Pharmaceutical Industries ( TEVA) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.5%. By the end of trading, Teva Pharmaceutical Industries rose $0.49 (1.2%) to $40.59 on average volume. Throughout the day, 3,220,194 shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 3,572,800 shares. The stock ranged in a price between $40.00-$40.83 after having opened the day at $40.03 as compared to the previous trading day's close of $40.10. Other companies within the Drugs industry that increased today were: Biocryst Pharmaceuticals ( BCRX), up 51.2%, TrovaGene ( TROV), up 21.3%, Chelsea Therapeutics International ( CHTP), up 16.0% and PetMed Express ( PETS), up 13.6%.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $34.1 billion and is part of the health care sector. Shares are up 7.4% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Teva Pharmaceutical Industries a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its attractive valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and a generally disappointing performance in the stock itself.

On the negative front, Mast Therapeutics ( MSTX), down 34.6%, Oxygen Biotherapeutics ( OXBT), down 23.9%, CEL-SCI Corporation ( CVM), down 17.1% and Senesco Technologies ( SNTI), down 12.7% , were all laggards within the drugs industry with Allergan ( AGN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

S&P 500 and Dow Score Records With Wall Street Upbeat Ahead of Fed

S&P 500 and Dow on Track for Records With Markets in Good Mood Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Dow and S&P 500 Reach New Intraday Highs With Markets in Good Mood Ahead of Fed

Teva's New CEO Brings This Secret Weapon